Replies to post #233954 on Biotech Values

[DewDiligence]

AVLR enters the RSV arena with novel MoA:

https://www.businesswire.com/news/home/20201217005253/en

Not much of a threat to ENTA’s RSV program at this point, IMO.

[DewDiligence]

ALVR -65%/PM on phase-3 futility—program termination:

https://www.globenewswire.com/news-release/2023/12/22/2800535/0/en/AlloVir-Provides-Updates-on-Phase-3-Clinical-Development-Program-for-Posoleucel-an-Allogeneic-Virus-Specific-T-Cell-Therapy.html

The stock is down 95% from its 2020 IPO (#msg-157261592).